Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5654614 | 1.00 | ADRA2B (0.47) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL18522813 | 1.00 | ADRA2B (0.47) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL5569488 | 0.85 | ADRA2B (0.51) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL5569486 | 0.85 | ADRA2B (0.51) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL20463999 | 0.82 | KMT2A (0.38) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL20467555 | 0.82 | KMT2A (0.38) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL21866479 | 0.79 | MEN1 (0.41) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL16197369 | 0.79 | MEN1 (0.41) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL5564359 | 0.78 | ADRA2B (0.55) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL44989 | 0.77 | SIGMAR1 (0.41) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607996-B1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2023-01-04 | — | — | EP | disclosed |
| US-20220105195-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2022-04-07 | — | — | US | disclosed |
| EP-3388427-B1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PF MEDICAMENT (FR) | 2022-01-19 | — | — | EP | disclosed |
| EP-3607996-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2020-02-12 | — | — | EP | disclosed |
| EP-3134125-B1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2019-10-09 | — | — | EP | disclosed |
| EP-3498301-A1 | KIT COMPRISING IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2019-06-19 | — | — | EP | disclosed |
| EP-3134124-B1 | IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2019-02-20 | — | — | EP | disclosed |
| EP-2989088-B1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PF MEDICAMENT (FR) | 2017-09-27 | — | — | EP | disclosed |
| WO-2017072196-A1 | COMPOSITION FOR THE TREATMENT OF IGF-1R EXPRESSING CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-05-04 | — | — | WO | disclosed |
| US-7312343-B2 | N-benzyl-protected dialkyl acetal derivatives undergo desired aldol reaction with high diastereoselectivity using a Mukaiyama aldol reaction; intermediates in the synthesis of other products, including, e.g. Dolastatin 10 | HOFFMANN-LA ROCHE INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20050272665-A1 | Synthesis of alpha-amino-beta-alkoxy-carboxylic acid esters | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272665-A1 | Synthesis of alpha-amino-beta-alkoxy-carboxylic acid esters | ALDH7A1, BCAT1, BCAT2 | ADRA2B 420/4885ADRA2C 515/4885SLC6A2 1670/4885 |
| US-20220105195-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | KRTCAP2, DDOST, DAD1 | ADRA2B 2865/4885ADRA2C 2959/4885SLC6A2 2388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.